propafenone has been researched along with Disease Models, Animal in 19 studies
Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.
propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Previously reported studies identified analogues of propafenone that had potent antimalarial activity, reduced cardiac ion channel activity, and properties that suggested the potential for clinical development for malaria." | 7.78 | Lead optimization of antimalarial propafenone analogues. ( Clark, JA; Connelly, MC; Derisi, JL; Furimsky, A; Gow, J; Guiguemde, WA; Guy, RK; Iyer, LV; Kyle, DE; Lemoff, A; Lowes, D; Mirsalis, J; Parman, T; Pradhan, A; Sigal, M; Tang, L; Wilson, E; Zhu, F, 2012) |
| "The effects of procainamide and propafenone on the composition of the excitable gap (EG) were studied in a canine model of atrial flutter (AFI) around the tricuspid valve." | 7.69 | Effects of procainamide and propafenone on the composition of the excitable gap in canine atrial reentry tachycardia. ( Derakhchan, K; Kus, T; Lambert, C; Pagé, P, 1994) |
| "The efficacy of intravenous cibenzoline (3 mg/kg), propafenone (4 mg/kg), and procainamide (20 mg/kg) against inducible sustained and nonsustained ventricular tachycardias (VT) was evaluated in 12 conscious dogs with chronic isolated right ventricular (RV) infarction." | 7.67 | The efficacy of cibenzoline and propafenone against inducible sustained and nonsustained ventricular tachycardias in conscious dogs with isolated chronic right ventricular infarction: a comparative study with procainamide. ( Ino, T; Karagueuzian, HS; Mandel, WJ; Meesmann, M; Ohta, M; Peter, T; Sugi, K, 1986) |
| "Propafenone was continuously pumped (velocity=70 mg/kg per h) until the mean blood pressure dropped to 50% of basal level." | 5.56 | Detoxification effects of long-chain versus a mixture of medium- and long-chain triglyceride-based fat emulsion on propafenone poisoning. ( An, X; Mei, Y; Sun, H; Zhang, J, 2020) |
| "Propafenone at doses 60-90mg/kg significantly increased the threshold of seizures, in turn at doses 5-50mg/kg did not affect this parameter." | 3.88 | Influence of propafenone on the anticonvulsant activity of various novel antiepileptic drugs in the mouse maximal electroshock model. ( Banach, M; Borowicz-Reutt, KK; Popławska, M; Wróblewska, D, 2018) |
| "Previously reported studies identified analogues of propafenone that had potent antimalarial activity, reduced cardiac ion channel activity, and properties that suggested the potential for clinical development for malaria." | 3.78 | Lead optimization of antimalarial propafenone analogues. ( Clark, JA; Connelly, MC; Derisi, JL; Furimsky, A; Gow, J; Guiguemde, WA; Guy, RK; Iyer, LV; Kyle, DE; Lemoff, A; Lowes, D; Mirsalis, J; Parman, T; Pradhan, A; Sigal, M; Tang, L; Wilson, E; Zhu, F, 2012) |
| " We tested the efficacy and proarrhythmic potential of KCB-328, dofetilide and propafenone in the pacing induced canine model of atrial fibrillation (AF)." | 3.72 | Evaluation of KCB-328, a new IKr blocking antiarrhythmic agent in pacing induced canine atrial fibrillation. ( Chandra, P; Danilo, P; Kim, HY; Lee, K; Rosen, MR; Rosen, TS; Yeom, ZH, 2004) |
| "The effects of procainamide and propafenone on the composition of the excitable gap (EG) were studied in a canine model of atrial flutter (AFI) around the tricuspid valve." | 3.69 | Effects of procainamide and propafenone on the composition of the excitable gap in canine atrial reentry tachycardia. ( Derakhchan, K; Kus, T; Lambert, C; Pagé, P, 1994) |
| "The efficacy of intravenous cibenzoline (3 mg/kg), propafenone (4 mg/kg), and procainamide (20 mg/kg) against inducible sustained and nonsustained ventricular tachycardias (VT) was evaluated in 12 conscious dogs with chronic isolated right ventricular (RV) infarction." | 3.67 | The efficacy of cibenzoline and propafenone against inducible sustained and nonsustained ventricular tachycardias in conscious dogs with isolated chronic right ventricular infarction: a comparative study with procainamide. ( Ino, T; Karagueuzian, HS; Mandel, WJ; Meesmann, M; Ohta, M; Peter, T; Sugi, K, 1986) |
| "Propafenone was continuously pumped (velocity=70 mg/kg per h) until the mean blood pressure dropped to 50% of basal level." | 1.56 | Detoxification effects of long-chain versus a mixture of medium- and long-chain triglyceride-based fat emulsion on propafenone poisoning. ( An, X; Mei, Y; Sun, H; Zhang, J, 2020) |
| "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is caused by mutations in the cardiac ryanodine receptor (RyR2) or calsequestrin (Casq2) and can be difficult to treat." | 1.37 | Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia. ( Faggioni, M; Hasdemir, C; Hwang, HS; Knollmann, BC; Laver, D; Mehra, D; Turhan, K; Yin, H, 2011) |
| "Interventional elimination of chronic persistent atrial fibrillation (AFib) remains difficult." | 1.32 | Electrophysiological mapping and histological examinations of the swine atrium with sustained (> or =24 h) atrial fibrillation: a suitable animal model for studying human atrial fibrillation. ( Chen, SP; Du, CC; Huang, SK; Lai, LP; Lee, WC; Lien, WP; Lin, CS; Lin, JL; Tseng, YZ; Wu, TJ; Yang, PC, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.26) | 18.7374 |
| 1990's | 3 (15.79) | 18.2507 |
| 2000's | 4 (21.05) | 29.6817 |
| 2010's | 7 (36.84) | 24.3611 |
| 2020's | 4 (21.05) | 2.80 |
| Authors | Studies |
|---|---|
| Lowes, D | 1 |
| Pradhan, A | 1 |
| Iyer, LV | 1 |
| Parman, T | 1 |
| Gow, J | 1 |
| Zhu, F | 1 |
| Furimsky, A | 1 |
| Lemoff, A | 1 |
| Guiguemde, WA | 1 |
| Sigal, M | 1 |
| Clark, JA | 1 |
| Wilson, E | 1 |
| Tang, L | 1 |
| Connelly, MC | 1 |
| Derisi, JL | 1 |
| Kyle, DE | 1 |
| Mirsalis, J | 1 |
| Guy, RK | 1 |
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Xu, H | 1 |
| Yan, ZZ | 1 |
| Guo, MB | 1 |
| An, R | 1 |
| Wang, X | 1 |
| Zhang, R | 1 |
| Mou, YH | 1 |
| Hou, Z | 1 |
| Guo, C | 1 |
| An, X | 1 |
| Mei, Y | 1 |
| Sun, H | 1 |
| Zhang, J | 1 |
| Holmes, AP | 1 |
| Saxena, P | 1 |
| Kabir, SN | 1 |
| O'Shea, C | 1 |
| Kuhlmann, SM | 1 |
| Gupta, S | 1 |
| Fobian, D | 1 |
| Apicella, C | 1 |
| O'Reilly, M | 1 |
| Syeda, F | 1 |
| Reyat, JS | 1 |
| Smith, GL | 1 |
| Workman, AJ | 1 |
| Pavlovic, D | 1 |
| Fabritz, L | 1 |
| Kirchhof, P | 1 |
| Borowicz-Reutt, KK | 2 |
| Popławska, M | 1 |
| Banach, M | 2 |
| Wróblewska, D | 1 |
| Faggioni, M | 2 |
| Savio-Galimberti, E | 1 |
| Venkataraman, R | 1 |
| Hwang, HS | 2 |
| Kannankeril, PJ | 1 |
| Darbar, D | 1 |
| Knollmann, BC | 2 |
| Desaphy, JF | 1 |
| Carbonara, R | 1 |
| Costanza, T | 1 |
| Conte Camerino, D | 1 |
| Piskorska, B | 1 |
| Niu, G | 1 |
| Scherlag, BJ | 1 |
| Lu, Z | 1 |
| Ghias, M | 1 |
| Zhang, Y | 1 |
| Patterson, E | 1 |
| Dasari, TW | 1 |
| Zacharias, S | 1 |
| Lazzara, R | 1 |
| Jackman, WM | 1 |
| Po, SS | 1 |
| Hasdemir, C | 1 |
| Laver, D | 1 |
| Mehra, D | 1 |
| Turhan, K | 1 |
| Yin, H | 1 |
| Lin, JL | 1 |
| Lai, LP | 1 |
| Lin, CS | 1 |
| Du, CC | 1 |
| Wu, TJ | 1 |
| Chen, SP | 1 |
| Lee, WC | 1 |
| Yang, PC | 1 |
| Tseng, YZ | 1 |
| Lien, WP | 1 |
| Huang, SK | 1 |
| Chandra, P | 1 |
| Rosen, TS | 1 |
| Yeom, ZH | 1 |
| Lee, K | 1 |
| Kim, HY | 1 |
| Danilo, P | 1 |
| Rosen, MR | 1 |
| Derakhchan, K | 1 |
| Pagé, P | 1 |
| Lambert, C | 1 |
| Kus, T | 2 |
| Aupetit, JF | 2 |
| Timour, Q | 2 |
| Larbre, JP | 2 |
| Loufoua-Moundanga, J | 2 |
| Kioueh, I | 1 |
| Lopez, M | 1 |
| Faucon, G | 2 |
| Mensour, B | 1 |
| Jalil, E | 1 |
| Vinet, A | 1 |
| Gerentes-Chassagne, I | 1 |
| Karagueuzian, HS | 1 |
| Sugi, K | 1 |
| Ohta, M | 1 |
| Meesmann, M | 1 |
| Ino, T | 1 |
| Peter, T | 1 |
| Mandel, WJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of (R) and (S) Propafenone for Prevention of Atrial Fibrillation Induction[NCT02710669] | Phase 1/Phase 2 | 193 participants (Actual) | Interventional | 2016-10-31 | Terminated (stopped due to Study halted/terminated prematurely due to COVID.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Inducibility of atrial fibrillation (AF) or atrial flutter (AFL) expressed as an ordinal variable based on stage of the induction protocol.~Stage 1 measured the AV block (Wenckebach) cycle length (AVBCL), AV node effective refractory period (AVN ERP) and atrial ERP (AERP). AVN ERP and AERP were measured at drive trains (S1) of 600 ms and 450 ms. Extrastimuli (S2) were introduced starting at a coupling interval of 500ms and decremented by 10ms with each pacing train.~Stage 2 consisted of 15-beat bursts from the CS proximal electrode. The starting cycle length was 250ms, which was decremented by 10ms with each burst. A 10-second rest period was used between bursts. Step 2 was complete when 1:1 atrial capture was lost or a minimum cycle length of 180ms was reached.~Stage 3 consisted of 15-second bursts. The cycle length used for the bursts was the fastest cycle length achieved during Step 2 that maintained 1:1 atrial conduction." (NCT02710669)
Timeframe: Twenty minutes post-dosage to end of induction protocol (approximately 10 minutes)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Stage 1 | Stage 2 | Stage 3 | Non-inducible AF/AFL | |
| (R)-Propafenone | 5 | 28 | 27 | 11 |
| (S)-Propafenone | 5 | 31 | 24 | 15 |
| Placebo | 1 | 3 | 8 | 7 |
A rapid atrial pacing protocol was used to attempt to induce atrial fibrillation/atrial flutter. Twenty minutes after start of the study drug, participants underwent placement of a decapolar coronary sinus catheter. Pacing was performed from the proximal electrode at 20 milliamps and a pulse width of 2 ms. Bursts from the CS proximal electrode were induced to attempt atrial fibrillation. (NCT02710669)
Timeframe: Twenty minutes post-dosage to end of induction protocol (approximately 10 minutes)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Sustained AF and/or AFL induced | Non-sustained AF and/or AFL induced | |
| (R)-Propafenone | 60 | 11 |
| (S)-Propafenone | 60 | 15 |
| Placebo | 12 | 7 |
A rapid atrial pacing protocol was used to attempt to induce atrial flutter. Twenty minutes after start of the study drug, participants underwent placement of a decapolar coronary sinus catheter. Pacing was performed from the proximal electrode at 20 milliamps and a pulse width of 2 ms. Bursts from the CS proximal electrode were induced to attempt atrial flutter. (NCT02710669)
Timeframe: Twenty minutes post-dosage to end of induction protocol (approximately 10 minutes)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Sustained AFL | Non-Sustained AFL | |
| (R)-Propafenone | 23 | 48 |
| (S)-Propafenone | 26 | 49 |
| Placebo | 1 | 18 |
19 other studies available for propafenone and Disease Models, Animal
| Article | Year |
|---|---|
Lead optimization of antimalarial propafenone analogues.
Topics: Administration, Oral; Animals; Antimalarials; Chloroquine; Cytochrome P-450 CYP2D6; Cytochrome P-450 | 2012 |
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Lead optimization generates selenium-containing miconazole CYP51 inhibitors with improved pharmacological profile for the treatment of fungal infections.
Topics: 14-alpha Demethylase Inhibitors; Animals; Antifungal Agents; Binding Sites; Biofilms; Candida; Candi | 2021 |
Detoxification effects of long-chain versus a mixture of medium- and long-chain triglyceride-based fat emulsion on propafenone poisoning.
Topics: Animals; Disease Models, Animal; Fat Emulsions, Intravenous; Male; Poisoning; Propafenone; Rats; Rat | 2020 |
Atrial resting membrane potential confers sodium current sensitivity to propafenone, flecainide and dronedarone.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease Models, Animal; Dro | 2021 |
Influence of propafenone on the anticonvulsant activity of various novel antiepileptic drugs in the mouse maximal electroshock model.
Topics: Animals; Anticonvulsants; Brain; Disease Models, Animal; Drug Interactions; Electroshock; Female; Me | 2018 |
Suppression of spontaneous ca elevations prevents atrial fibrillation in calsequestrin 2-null hearts.
Topics: Animals; Atrial Fibrillation; Calcium; Calsequestrin; Cardiac Pacing, Artificial; Disease Models, An | 2014 |
Preclinical evaluation of marketed sodium channel blockers in a rat model of myotonia discloses promising antimyotonic drugs.
Topics: Animals; Carbamazepine; Disease Models, Animal; Flecainide; HEK293 Cells; Humans; Mexiletine; Muscle | 2014 |
Propafenone enhances the anticonvulsant action of classical antiepileptic drugs in the mouse maximal electroshock model.
Topics: Animals; Anticonvulsants; Avoidance Learning; Brain; Carbamazepine; Disease Models, Animal; Dose-Res | 2016 |
An acute experimental model demonstrating 2 different forms of sustained atrial tachyarrhythmias.
Topics: Acetylcholine; Acute Disease; Animals; Anti-Arrhythmia Agents; Atrial Appendage; Atrial Fibrillation | 2009 |
Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.
Topics: Analysis of Variance; Animals; Anti-Arrhythmia Agents; Calcium Channel Blockers; Calsequestrin; Defi | 2011 |
Electrophysiological mapping and histological examinations of the swine atrium with sustained (> or =24 h) atrial fibrillation: a suitable animal model for studying human atrial fibrillation.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Body Surface Potential Mapping; Cardiac Pacing | 2003 |
Evaluation of KCB-328, a new IKr blocking antiarrhythmic agent in pacing induced canine atrial fibrillation.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease Models, Animal; Dog | 2004 |
Effects of procainamide and propafenone on the composition of the excitable gap in canine atrial reentry tachycardia.
Topics: Action Potentials; Anesthesia; Animals; Atrial Flutter; Atrial Function; Chloralose; Diastole; Disea | 1994 |
Arrhythmogenicity of antiarrhythmic drugs and intraventricular conduction disorders: possible aggravation by myocardial ischemia--study in the porcine in situ heart.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Models, Animal; Electrocardiography; | 1993 |
Influence of propafenone on resetting and termination of canine atrial flutter.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Flutter; Blood Pressure; Cardiac Pacing, | 2000 |
[Arrhythmogenic risk of antiarrhythmic drugs: study with class Ic drugs during myocardial ischemia].
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Coronary Disease; | 1991 |
The efficacy of cibenzoline and propafenone against inducible sustained and nonsustained ventricular tachycardias in conscious dogs with isolated chronic right ventricular infarction: a comparative study with procainamide.
Topics: Animals; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Disease Models, Animal; Dogs; Drug Eval | 1986 |